<DOC>
	<DOCNO>NCT02830399</DOCNO>
	<brief_summary>It 's prospective , multicentric , randomize , control study concern 84 patient treatment-resistant depression ( TRD ) . The aim study evaluate augmentation Electroconvulsive therapy ( ECT ) repeat Transcranial Magnetic Stimulation ( rTMS ) . The primary outcome depressive symptom intensity measure Hamilton Rating Scale For Depression ( HAMD-21 item ) 5 ECT . The secondary outcome evaluate safety particularly cognitive effect association .</brief_summary>
	<brief_title>Clinical Trial Efficacy rTMS Improve ECT Treatment-Resistant Depression</brief_title>
	<detailed_description>Included patient adult , age 18 70 year , major depression ( Hamilton Rating scale Depression , HAMD ≥ 15 ) . Patients n't experience concern repeat Transcranial Magnetic Stimulation ( rTMS ) . Patients treatment-resistant depression ( TRD ) assign two treatment group addition current pharmacotherapy regimen : one group receive 5 active-rTMS Electroconvulsive therapy ( ECT ) one receive sham-rTMS ECT . The depressive symptom cognitive function evaluate rTMS , 5 rTMS 5 ECT .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Patients Major Depressive Disorder ( HAMD≥15 ) Level resistance ≥ 3 ( Thase Rush ) Participants give inform , write consent Contraindication Electroconvulsive therapy ( ECT ) , repeat Transcranial Magnetic Stimulation ( rTMS ) , Magnetic Resonance Imaging ( MRI ) , anesthesia History epilepsy ; severe neurological systemic disorder could significantly affect cognition Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>treatment-resistant-depression</keyword>
	<keyword>rTMS</keyword>
	<keyword>ECT</keyword>
	<keyword>Augmentation strategy</keyword>
</DOC>